PLSE

#1544
Pulse Biosciences, Inc - Common Stock
52.6 7 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
52.00
53.45
Jahresspanne
12.56
54.39
Tagesänderung
+1.11%
Monatliche Änderung
+46.31%
6 month change
+190.35%
Jahresänderung
+190.19%
Vorheriger Schlusskurs
52.0 9
Open
53.3 2
Tief
52.0 0
Hoch
53.4 5
Volumen
277
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
PULSE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
PULSE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
PULSE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
PULSE BIOSCIENCES, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K

PULSE BIOSCIENCES, INC. current report, Q1 FY2025

Full document

Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on January 21, 2025. The filing reports on late-breaking clinical data from the Company's first-in-human feasibility study of its Nanosecond PFA 360° Cardiac Catheter System.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements.

Material Changes and Clinical Results

The Company announced results from a study involving 77 patients treated by six investigators. The initial cohort of 30 patients was evaluated at approximately three months post-procedure. Key clinical metrics include:

  • Lesion Success: 100% of lesions achieved acute conduction block.
  • PVI Success Rate: 92.4% (109/118) at approximately 3 months.
  • Ablation Time: Total Pulmonary Vein Isolation (PVI) ablation time averaged 11.6 ± 4.5 minutes.
  • Procedure Efficiency: Total procedure time averaged 88.3 ± 30.1 minutes; fluoroscopy time averaged 6.9 ± 2.4 minutes.
  • Dwell Time: Left atrial dwell time averaged 29.6 ± 15.3 minutes.

Outlook, Risks, and Safety Profile

The study reported a safety profile with 1 Primary Serious Adverse Event (SAE) involving cardiac perforation. Additionally, 2 Adverse Events (AEs) were recorded: vertigo (managed conservatively) and creatinine elevation (treated with IV saline). All reported AEs resolved without sequelae. The filing incorporates a press release as Exhibit 99.1 for further details.

Investor Verification Checklist

  • Verify the full text of the press release attached as Exhibit 99.1 for detailed methodology and statistical analysis.
  • Confirm the long-term durability of the 92.4% PVI success rate beyond the 3-month mark.
  • Review the specific circumstances surrounding the single cardiac perforation SAE to assess procedural risk.
  • Check subsequent filings for updates on the remaining 47 patients in the study cohort.

Nachrichten